Tendinopathy When Medication Isn't Enough

Why Medications Alone Fall Short in Chronic Tendinopathy

Chronic tendinopathy is not primarily an inflammatory condition. That distinction matters. The tissue changes seen on histology, including disorganized collagen fibers, increased ground substance, and neovascularization without significant inflammatory cell infiltration, explain why anti-inflammatory drugs provide relief without repair [1].

A 2010 Cochrane review of NSAIDs for Achilles tendinopathy found no RCTs meeting inclusion criteria, highlighting a striking evidence gap for one of the most commonly prescribed drug classes in musculoskeletal medicine [2]. For lateral elbow tendinopathy, topical and oral NSAIDs reduce pain scores at 4 weeks, but no trial has demonstrated structural tendon improvement on imaging beyond 8 weeks.

Corticosteroid injections tell a more cautionary story. A landmark RCT by Coombes et al. (N=165) published in JAMA showed that corticosteroid injection for lateral epicondylalgia produced better outcomes than placebo at 4 weeks but significantly worse outcomes at 26 and 52 weeks, with recurrence rates of 72% in the steroid group versus 8% in the wait-and-see group [3]. The Endocrine Society's clinical guidance notes that repeated local glucocorticoid exposure may impair tenocyte proliferation and collagen synthesis [4].

This is the core problem: the drugs that feel helpful in the short run may actively hinder long-term tendon remodeling.

Eccentric and Progressive Loading: The Foundation of Non-Drug Management

If one intervention had to be chosen for chronic tendinopathy, eccentric loading programs hold the most consistent RCT support across tendon sites. The concept is simple but counterintuitive. You load the tendon during its lengthening phase.

Alfredson's original eccentric protocol for midportion Achilles tendinopathy, published in 1998, reported that 82 of 101 tendons (82%) achieved full return to pre-injury activity levels after 12 weeks of twice-daily eccentric heel drops [5]. A systematic review by Malliaras et al. in the British Journal of Sports Medicine confirmed that eccentric-only programs and combined heavy slow resistance (HSR) programs produce comparable outcomes for Achilles and patellar tendinopathy, with patient satisfaction rates between 60% and 90% at 3 months [6].

Heavy slow resistance training, introduced by Kongsgaard et al. in a 2009 Scandinavian Journal of Medicine & Science in Sports RCT (N=39), showed equivalent clinical improvement to eccentric training for patellar tendinopathy at 12 weeks, with superior patient satisfaction scores (100% vs. 80%) [7]. The HSR approach uses bilateral movements (leg press, hack squat) at progressively heavier loads (6RM progressing to 4RM over 12 weeks).

For acute pain flares during rehab, isometric holds offer rapid analgesia. Rio et al. demonstrated in a crossover study that a single bout of isometric quadriceps contractions (5 x 45-second holds at 70% maximal voluntary contraction) reduced patellar tendon pain by a mean of 6.8 points on a 10-point numeric rating scale, an effect lasting at least 45 minutes post-exercise [8]. That makes isometrics a practical in-season tool for athletes who need immediate pain reduction without medication.

The loading progression for most tendinopathies follows a predictable sequence: isometric loading (pain management) progresses to isotonic eccentric or HSR loading (tendon remodeling), then to energy-storage exercises (plyometrics, sport-specific drills), and finally to return-to-sport. Each phase typically spans 3-6 weeks, though individual response varies.

Extracorporeal Shockwave Therapy (ESWT)

ESWT delivers focused acoustic energy pulses to the affected tendon, stimulating a local healing response through mechanotransduction. The mechanism appears to involve upregulation of lubricin expression and increased tenocyte proliferation [9].

The strongest evidence sits with calcific rotator cuff tendinopathy. A meta-analysis by Defined et al. in the Journal of Orthopaedic Research pooled 11 RCTs and found high-energy focused ESWT superior to sham for pain reduction (standardized mean difference -1.39, 95% CI -1.76 to -1.02) and calcium deposit resorption [10]. For non-calcific tendinopathies, the picture is more mixed. A 2020 BMJ systematic review of ESWT for lateral elbow tendinopathy concluded modest short-term benefit over placebo but noted high heterogeneity across trials [11].

Typical protocols deliver 1,500 to 2,500 impulses per session at 0.12-0.32 mJ/mm² energy flux density, repeated weekly for 3-5 sessions. Pain during treatment correlates with energy dose and is expected. The number needed to treat (NNT) for calcific shoulder tendinopathy ranges from 3 to 5.

ESWT should not be used over open growth plates, areas of active infection, or in patients on anticoagulation therapy. It works best as an adjunct to loading programs, not a replacement for them.

Platelet-Rich Plasma (PRP) Injections

PRP concentrates autologous growth factors (PDGF, TGF-beta, VEGF, IGF-1) from a patient's own blood draw, delivering them directly to the degenerated tendon. The theoretical appeal is strong: supply the tendon with concentrated repair signals.

For lateral epicondylar tendinopathy, Mishra and Pavelko's initial RCT and the subsequent larger trial by Gosens et al. (N=100) showed PRP superior to corticosteroid injection at 1 year, with 73% pain reduction in the PRP group versus 51% in the steroid group on the DASH score (P<0.001) [12]. A 2014 meta-analysis in the American Journal of Sports Medicine pooled 10 RCTs across tendon locations and found PRP superior to control for pain and function at 24 weeks but not at earlier time points, suggesting PRP benefits emerge slowly [13].

The Achilles tendinopathy data is less convincing. The PRP-Achilles trial by de Vos et al. (N=54) found no difference between PRP and saline injection at 24 weeks when both groups also performed eccentric exercises [14]. This raises an important point: PRP may add little when stacked on top of an already effective loading program for certain tendon sites.

Preparation matters. Leukocyte-rich PRP (LR-PRP) contains neutrophils and pro-inflammatory cytokines that may be counterproductive in a degenerative tendon. Leukocyte-poor PRP (LP-PRP) delivers growth factors without the inflammatory payload. A 2019 network meta-analysis in the British Journal of Sports Medicine suggested LP-PRP produces superior outcomes for tendinopathy compared with LR-PRP [15]. Patients considering PRP should ask their provider about the specific preparation method, platelet concentration, and leukocyte content.

Insurance coverage for PRP remains inconsistent across U.S. payers, with most plans considering it investigational for tendinopathy.

BPC-157: Preclinical Promise, Clinical Caution

Body Protection Compound-157 (BPC-157) is a synthetic pentadecapeptide derived from a protective protein found in human gastric juice. Preclinical studies in rat models have shown BPC-157 accelerates Achilles tendon healing after transection, with increased collagen fiber density and improved biomechanical strength at 14 days compared with saline controls [16].

The proposed mechanisms include upregulation of growth hormone receptor expression in tendon tissue, enhanced nitric oxide synthesis promoting local blood flow, and modulation of the FAK-paxillin signaling pathway involved in cell migration and tendon remodeling [17]. These pathways overlap with known mechanisms of tendon repair, making the preclinical signal biologically plausible.

The problem is straightforward: no completed Phase II or Phase III human RCT data exists for BPC-157 in tendinopathy as of mid-2026. Clinicians in regenerative medicine and sports medicine do prescribe BPC-157 off-label, typically via subcutaneous injection near the affected tendon at doses of 200-500 mcg daily for 4-8 weeks. Some practitioners use oral formulations, though bioavailability data for oral BPC-157 reaching tendon tissue is lacking.

The FDA has not approved BPC-157 for any indication. Patients exploring this option should do so only under direct physician supervision, with realistic expectations calibrated to the current evidence level (preclinical, not clinical). The safety profile appears favorable in animal studies, with no reported organ toxicity at supraphysiologic doses, but absence of evidence is not evidence of absence in humans [16].

Other Non-Pharmacologic Interventions Worth Knowing

Several additional approaches have RCT support, though effect sizes tend to be smaller or the evidence base thinner than for loading programs and ESWT.

Glyceryl trinitrate (GTN) patches. Topical GTN applied over the tendon delivers nitric oxide, a molecule involved in collagen synthesis. Paoloni et al. conducted an RCT (N=65) showing that continuous GTN patch application combined with rehabilitation produced superior outcomes to rehabilitation alone for non-insertional Achilles tendinopathy at 24 weeks (78% asymptomatic vs. 49%, P=0.03) [18]. Headache is the most common side effect, affecting 30-40% of users and causing discontinuation in roughly 15%.

Sclerosing injections (polidocanol). Neovascularization and accompanying nerve ingrowth into the degenerated tendon contribute to pain in chronic Achilles and patellar tendinopathy. Alfredson and Ohberg injected polidocanol under ultrasound guidance targeting neovessels and reported 8 of 10 patients pain-free at 8-month follow-up in their pilot study [19]. Subsequent RCTs have shown mixed results, with a 2013 randomized trial finding no superiority over lidocaine-adrenaline injection at 12 months.

Dry needling and tendon fenestration. Ultrasound-guided percutaneous needle tenotomy creates microtrauma within the degenerated tendon to stimulate a healing response. A systematic review in the British Journal of Sports Medicine found moderate evidence for short-term pain reduction in lateral epicondylar and rotator cuff tendinopathy, though study quality was generally low [20].

Load management and activity modification. This is less glamorous than injections but equally important. Tendinopathy is a load-capacity mismatch. The tendon cannot tolerate the demands placed on it. Identifying and temporarily reducing aggravating loads (hill running for Achilles, overhead volume for rotator cuff, grip-intensive tasks for lateral elbow) while building capacity through progressive loading is the single most important behavioral change a patient can make.

Building a Treatment Hierarchy: What to Try and When

Not every intervention belongs at the same point in the treatment timeline. A rational approach sequences therapies based on evidence strength and invasiveness.

Weeks 1-4: Begin a structured loading program (eccentric or HSR) matched to the affected tendon. Use isometric holds for acute pain flares. Modify aggravating activities. Continue any prescribed medications for comfort but understand they are not fixing the tendon.

Weeks 4-12: If loading alone produces insufficient progress (defined as less than a 30% improvement on a validated patient-reported outcome measure like the VISA-A or VISA-P), consider adding ESWT for calcific tendinopathy or GTN patches for Achilles tendinopathy as adjuncts. Do not abandon the loading program.

Weeks 12-24: For refractory cases with ongoing pain and functional limitation despite quality rehab, LP-PRP injection is reasonable for lateral epicondylar tendinopathy. The decision to try PRP for Achilles tendinopathy is less evidence-supported. BPC-157 sits in this timeframe for patients willing to accept an investigational agent under physician supervision.

Beyond 6 months: If 6 months of multimodal conservative care (supervised loading, at least one adjunct therapy, confirmed adherence) has failed, surgical consultation is appropriate. For Achilles tendinopathy, surgical options include open debridement, minimally invasive stripping, or plantaris release. For lateral epicondylar tendinopathy, arthroscopic ECRB release. Success rates for surgery in well-selected patients range from 70% to 90%, but selection bias in surgical case series is significant [21].

"The evidence consistently shows that the best predictor of success in tendinopathy management is not the specific treatment chosen but the patient's adherence to a progressive loading program over a sufficient duration," notes the 2018 International Scientific Tendinopathy Symposium consensus statement [22].

What the Research Says About Supplements and Nutrition

Patients searching for natural approaches to tendinopathy will encounter claims about collagen peptides, vitamin C, and curcumin. The evidence base here is thin but not entirely empty.

Shaw et al. published a 2017 RCT in the American Journal of Clinical Nutrition (N=8) showing that 15 g of gelatin enriched with vitamin C, consumed 60 minutes before exercise, doubled markers of collagen synthesis (procollagen I N-terminal propeptide) in engineered ligament constructs [23]. This is a mechanistic study with a very small sample. It does not prove that collagen supplements repair tendinopathy. But the biological signal is consistent with the known role of vitamin C as a cofactor for prolyl hydroxylase, an enzyme required for stable collagen triple-helix formation.

Curcumin, the active compound in turmeric, has anti-inflammatory and antioxidant properties demonstrated in vitro and in animal models of tendon injury. A 2021 systematic review identified no completed human RCTs of curcumin specifically for tendinopathy [24]. Patients choosing to supplement with curcumin should use bioavailability-enhanced formulations (e.g., those containing piperine or phospholipid complexes) and understand this is adjunctive, not primary therapy.

Adequate protein intake (1.6-2.2 g/kg/day for active individuals) supports the anabolic environment needed for tendon remodeling. Severe caloric restriction or relative energy deficiency in sport (RED-S) impairs collagen synthesis and is a recognized risk factor for tendinopathy in athletes [25].

When to Seek Imaging and Specialist Referral

Not every chronic tendon pain requires an MRI. But certain clinical features should prompt imaging and specialist evaluation.

Acute-onset severe pain with a palpable gap in the tendon suggests partial or complete rupture, not tendinopathy. This requires urgent imaging and likely surgical consultation. Night pain that wakes the patient, systemic symptoms (fever, weight loss, morning stiffness lasting more than 30 minutes), or tendon pain in multiple sites simultaneously raises the differential beyond simple tendinopathy to include inflammatory arthropathy, fluoroquinolone-associated tendon disease, or statin-associated tendon disorders [26].

Ultrasound is the preferred first-line imaging modality for tendinopathy. It is dynamic (the tendon can be evaluated during movement), comparatively inexpensive, and highly sensitive for neovascularization, tendon thickening, and partial tears. MRI adds value when the diagnosis is uncertain, when surgical planning requires detailed anatomic mapping, or when ultrasound is unavailable.

Referral to a sports medicine physician, orthopedic surgeon, or physiatrist is appropriate when 3 months of self-directed or physiotherapist-supervised loading has not produced meaningful improvement, when injection therapies are being considered, or when the clinical picture does not fit a straightforward tendinopathy pattern.

The minimum effective dose of physiotherapy-supervised loading is typically 2 sessions per week for 12 weeks, with a structured home program on non-supervised days. Anything less than that threshold makes it difficult to conclude that "conservative management has failed," because it was never adequately tried.